Pulmonary, Gastrointestinal and Urogenital PharmacologyMidcervical vagotomy precludes respiratory response to novel anti-inflammatory and anti-tumour drug ARVANIL (cas 128007-31-8) in rats
-
Add time:08/22/2019 Source:sciencedirect.com
ARVANIL (cas 128007-31-8) is a metabolically stable hybrid between anandamide and capsaicin. The present study was designed to test the role of the vagal pathway in post-arvanil respiratory and blood pressure responses. Respiratory and pressure changes evoked by an intravenous injection of arvanil were investigated in 21 urethane–chloralose anaesthetised and spontaneously breathing rats. In control neurally intact rats the effects of arvanil were checked to establish the appropriate dose of the drug. In the experimental group rats were challenged with arvanil while intact, following bilateral midcervical vagotomy and after subsequent supranodose vagotomy. In all neurally intact animals bolus injection of 0.8 mg/kg of arvanil into the right femoral vein induced a significant increase of tidal volume (+ 1 ± 0.11 ml; P < 0.01) and diaphragm activity (+ 1.72 ± 0.1 arbitrary units; P < 0.01) as well as hypertension (+ 31.9 ± 2.9 mm Hg; P < 0.001) and a fall in respiratory rate (−24.7 ± 0.4 breath/min; P < 0.001). Bilateral midcervical vagotomy precluded the alteration of respiratory parameters but did not eliminate blood pressure response. Arvanil-induced increase in mean arterial blood pressure still persisted after supranodose vagotomy. Results indicated that the respiratory effects evoked by arvanil administered via the peripheral circulation require intact midcervical vagi. Supranodose vagotomy failed to eliminate the hypertension evoked by arvanil.
We also recommend Trading Suppliers and Manufacturers of ARVANIL (cas 128007-31-8). Pls Click Website Link as below: cas 128007-31-8 suppliers
Prev:Short communicationARVANIL (cas 128007-31-8), olvanil, AM 1172 and LY 2183240 (various cannabinoid CB1 receptor agonists) increase the threshold for maximal electroshock-induced seizures in mice
Next:Role of VR1 and CB1 receptors in modelling of cardio-respiratory response to ARVANIL (cas 128007-31-8), an endocannabinoid and vanilloid hybrid, in rats) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- The Synthesis of N-Vanillyl-arachidonoyl-amide (ARVANIL (cas 128007-31-8)) and its Analogs: An Improved Procedure for the Synthesis of the Key Synthon Methyl 14-Hydroxy-(all-cis)-5,8,11-tetradecatrienoate08/29/2019
- ARVANIL (cas 128007-31-8)-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors08/28/2019
- Effect of ARVANIL (cas 128007-31-8) (N-arachidonoyl-vanillyl-amine), a nonpungent anandamide–capsaicin hybrid, on ion currents in NG108-15 neuronal cells08/27/2019
- ARVANIL (cas 128007-31-8) and anandamide up-regulate CD36 expression in human peripheral blood mononuclear cells08/26/2019
- Short CommunicationARVANIL (cas 128007-31-8), a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease08/25/2019
- ARVANIL (cas 128007-31-8) inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis08/24/2019
- Role of VR1 and CB1 receptors in modelling of cardio-respiratory response to ARVANIL (cas 128007-31-8), an endocannabinoid and vanilloid hybrid, in rats08/23/2019
- Short communicationARVANIL (cas 128007-31-8), olvanil, AM 1172 and LY 2183240 (various cannabinoid CB1 receptor agonists) increase the threshold for maximal electroshock-induced seizures in mice08/21/2019


